Hyperprogression and Immunotherapy: Fact, Fiction, or Alternative Fact?
Animals
Clinical Trials as Topic
Disease Progression
Humans
Immune Checkpoint Inhibitors
/ adverse effects
Immunoglobulin Fab Fragments
/ therapeutic use
Immunoglobulin Fc Fragments
/ adverse effects
Immunotherapy
/ adverse effects
Mice
Models, Immunological
Neoplasm Proteins
/ physiology
Neoplasms
/ diagnostic imaging
Nivolumab
/ therapeutic use
Progression-Free Survival
Retrospective Studies
Treatment Outcome
Tumor Burden
Tumor Microenvironment
cancer clinical trials
hyperprogressive disease
immune checkpoint inhibitors
immunotherapy
Journal
Trends in cancer
ISSN: 2405-8025
Titre abrégé: Trends Cancer
Pays: United States
ID NLM: 101665956
Informations de publication
Date de publication:
03 2020
03 2020
Historique:
received:
15
10
2019
revised:
02
01
2020
accepted:
06
01
2020
entrez:
27
2
2020
pubmed:
27
2
2020
medline:
2
6
2021
Statut:
ppublish
Résumé
Immunotherapy (IO) has altered the therapeutic landscape for multiple cancers. There are emerging data from retrospective studies on a subset of patients who do not benefit from IO, instead experiencing rapid progression with dramatic acceleration of disease trajectory, termed 'hyperprogressive disease' (HPD). The incidence of HPD ranges from 4% to 29% from the studies reported. Biological basis and mechanisms of HPD are currently being elucidated, with one theory involving the Fc region of antibodies. Another group has shown EGFR and MDM2/MDM4 amplifications in patients with HPD. This phenomenon has polarized oncologists who debate that this could still reflect the natural history of the disease. Thus, prospective studies are urgently needed to confirm the underlying biology, predict patients who are susceptible to HPD, and determine the modality of therapy post progression.
Identifiants
pubmed: 32101722
pii: S2405-8033(20)30018-2
doi: 10.1016/j.trecan.2020.01.005
pmc: PMC9726601
mid: NIHMS1569333
pii:
doi:
Substances chimiques
Immune Checkpoint Inhibitors
0
Immunoglobulin Fab Fragments
0
Immunoglobulin Fc Fragments
0
Neoplasm Proteins
0
Nivolumab
31YO63LBSN
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
181-191Subventions
Organisme : NCI NIH HHS
ID : R01 CA242845
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA273168
Pays : United States
Informations de copyright
Copyright © 2020 The Author(s). Published by Elsevier Inc. All rights reserved.
Références
Clin Cancer Res. 2019 Feb 1;25(3):989-999
pubmed: 30206165
Br J Cancer. 2012 Feb 28;106(5):854-7
pubmed: 22281665
Clin Cancer Res. 2014 Jan 1;20(1):246-52
pubmed: 24240109
N Engl J Med. 2018 May 17;378(20):1947-1948
pubmed: 29768155
Ann Oncol. 2019 Jul 1;30(7):1104-1113
pubmed: 30977778
Eur J Cancer. 2011 Nov;47(17):2512-6
pubmed: 21763126
Clin Cancer Res. 2017 Aug 1;23(15):4242-4250
pubmed: 28351930
Clin Cancer Res. 2017 Apr 15;23(8):1920-1928
pubmed: 27827313
Oncologist. 2020 Feb;25(2):94-98
pubmed: 32043794
Cancer Cell. 2015 Sep 14;28(3):285-95
pubmed: 26373277
Eur Urol. 2014 Apr;65(4):713-20
pubmed: 23993162
JAMA Oncol. 2018 Nov 1;4(11):1543-1552
pubmed: 30193240
JAMA Oncol. 2019 May 1;5(5):743
pubmed: 30896751
iScience. 2018 Nov 30;9:258-277
pubmed: 30439581
Immunol Rev. 2010 Jul;236:219-42
pubmed: 20636820
Cancer. 2019 Apr 15;125(8):1341-1349
pubmed: 30768786
PLoS Pathog. 2017 Jan 3;13(1):e1006120
pubmed: 28046066
Proc Natl Acad Sci U S A. 2019 May 14;116(20):9999-10008
pubmed: 31028147
Ann Oncol. 2017 Jul 01;28(7):1605-1611
pubmed: 28419181